A Clinical Study on Urinary Clusterin and Cystatin B in Dogs with Spontaneous Acute Kidney Injury
2024
Emilia Gordin | Sanna Viitanen | Daniel Gordin | Donald Szlosek | Sarah Peterson | Thomas Spillmann | Mary Anna Labato
Novel biomarkers are needed in diagnosing reliably acute kidney injury (AKI) in dogs and in predicting morbidity and mortality after AKI. Our hypothesis was that two novel tubular biomarkers, urinary clusterin (uClust) and cystatin B (uCysB), are elevated in dogs with AKI of different etiologies. In a prospective, longitudinal observational study, we collected serum and urine samples from 18 dogs with AKI of different severity and of various etiology and from 10 healthy control dogs. Urinary clusterin and uCysB were compared at inclusion between dogs with AKI and healthy controls and remeasured one and three months later. Dogs with AKI had higher initial levels of uClust (median 3593 ng/mL: interquartile range [IQR]: 1489&ndash:10,483) and uCysB (554 ng/mL: 29&ndash:821) compared to healthy dogs (70 ng/mL: 70&ndash:70 and 15 ng/mL: 15&ndash:15: p <: 0.001, respectively). Initial uCysB were higher in dogs that died during the one-month follow-up period (n = 10) (731 ng/mL: 517&ndash:940), compared to survivors (n = 8) (25 ng/mL: 15&ndash:417 (p = 0.009). Based on these results, uClust and especially uCysB are promising biomarkers of AKI. Further, they might reflect the severity of tubular injury, which is known to be central to the pathology of AKI.
显示更多 [+] 显示较少 [-]